Robin Meng

406 total citations
10 papers, 234 citations indexed

About

Robin Meng is a scholar working on Oncology, Hematology and Obstetrics and Gynecology. According to data from OpenAlex, Robin Meng has authored 10 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Hematology and 2 papers in Obstetrics and Gynecology. Recurrent topics in Robin Meng's work include Acute Lymphoblastic Leukemia research (2 papers), CAR-T cell therapy research (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). Robin Meng is often cited by papers focused on Acute Lymphoblastic Leukemia research (2 papers), CAR-T cell therapy research (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). Robin Meng collaborates with scholars based in United States, France and South Korea. Robin Meng's co-authors include Giovanni Abbadessa, Alexey Rak, Chen Zhu, Chih‐Wei Yu, Wei-Shou Hwang, Kenneth C. Anderson, Wen-Tsung Huang, Tsai‐Sheng Yang, Thomas G. Martin and Teh‐Ia Huo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Robin Meng

8 papers receiving 231 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Meng United States	5	118	73	65	50	49	10	234
Nebojša Manojlović Serbia	8	215 1.8×	25 0.3×	58 0.9×	22 0.4×	18 0.4×	25	277
Zhongmin Maxwell Wang Australia	10	210 1.8×	11 0.2×	49 0.8×	117 2.3×	27 0.6×	17	330
Jingquan Jia United States	10	114 1.0×	8 0.1×	116 1.8×	51 1.0×	25 0.5×	28	246
Brian Munneke United States	7	170 1.4×	38 0.5×	61 0.9×	54 1.1×	8 0.2×	13	337
Andy Boral United States	4	36 0.3×	72 1.0×	101 1.6×	63 1.3×	9 0.2×	4	287
Sunil Gandhi United States	6	84 0.7×	77 1.1×	132 2.0×	9 0.2×	3 0.1×	8	232
Nishi Kothari United States	12	238 2.0×	12 0.2×	93 1.4×	39 0.8×	20 0.4×	29	372
Meaghan Dendy United States	8	105 0.9×	73 1.0×	200 3.1×	10 0.2×	89 1.8×	11	345
Selena Dixon United Kingdom	2	70 0.6×	81 1.1×	105 1.6×	13 0.3×	16 0.3×	7	248
Marion Jacquin France	8	161 1.4×	12 0.2×	156 2.4×	128 2.6×	11 0.2×	16	340

Countries citing papers authored by Robin Meng

Since Specialization

Citations

This map shows the geographic impact of Robin Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Meng more than expected).

Fields of papers citing papers by Robin Meng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Meng. The network helps show where Robin Meng may publish in the future.

Co-authorship network of co-authors of Robin Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Meng. A scholar is included among the top collaborators of Robin Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Meng. Robin Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Herráez, A. Casado, Émeline Colomba, David S. Miller, et al.. (2025). 1119P Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775. Annals of Oncology. 36. S699–S700.

Paranjpe, Rutugandha, Chen Cai, Yezhou Sun, et al.. (2025). Molecular heterogeneity in dMMR/MSI-H endometrial cancer in the US.. Journal of Clinical Oncology. 43(16_suppl).

Jiang, Hong, B-Y. Ryoo, Maxime Chénard-Poirier, et al.. (2023). 1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results. Annals of Oncology. 34. S634–S634. 5 indexed citations

Fu, Siqing, Gerald S. Falchook, Minal Barve, et al.. (2023). Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors. Cancer Research. 83(7_Supplement). 2155–2155. 1 indexed citations

Yáñez, Eduardo, Christine Rojas, Anna Sureda, et al.. (2022). Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma. Blood. 140(Supplement 1). 12020–12021. 1 indexed citations

Cho, B.C., Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2021). LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Annals of Oncology. 32. S1428–S1428. 19 indexed citations

Meng, Robin, Caroline Even, Lisa Licitra, et al.. (2021). 435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma. SHILAP Revista de lepidopterología. A465–A465. 1 indexed citations

Martin, Thomas G., Marielle Chiron, Helgi van de Velde, et al.. (2019). Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 8(12). 1522–1522. 106 indexed citations

Zhu, Jun, Huiqiang Huang, Huan Chen, et al.. (2017). Plerixafor and granulocyte‐colony‐stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non−Hodgkin's lymphoma: a randomized Phase 3 study. Transfusion. 58(1). 81–87. 18 indexed citations

10.

Hsu, Chiun, Tsai‐Sheng Yang, Teh‐Ia Huo, et al.. (2012). Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology. 56(5). 1097–1103. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact